REG - LungLife AI, INC - Result of AGM

LungLife AIAnnouncement

04/05/2023 18:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230504:nRSD4930Ya&default-theme=true

RNS Number : 4930Y  LungLife AI, INC  04 May 2023

LungLife AI, Inc.

(the "Company" or "LungLife")

 

Result of Annual General Meeting

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung
cancer, announces that at its Annual General Meeting, held at earlier today,
all 10 resolutions put to members were passed on a poll.

 

The number of votes lodged by proxy for and against each of the resolutions
proposed, and the number of votes withheld was as follows:

 

  Resolution                                                                      Votes for   %       Votes against  %      Votes withheld
 Resolution 1 (Common)                                                            13,016,289  100.00  0              0.00   0

 TO receive the Annual Report and Accounts of the Company for the year ended 31
 December 2022 together with the directors' and auditor's reports thereon.
 Resolution 2 (Common)                                                            9,997,926   76.81   3,018,363      23.19  0

 TO approve the Directors' Remuneration Policy.
 Resolution 3 (Common)                                                            13,016,289  100.00  0              0.00   0

 TO receive the Directors' Remuneration Report for the year ended 31 December
 2022.
 Resolution 4 (Common)                                                            13,016,289  100.00  0              0.00   0

 THAT Roy Davis be, and hereby is, re-elected as a director of the Company to
 hold office until the conclusion of the next Annual General Meeting of the
 Company.
 Resolution 5 (Common)                                                            13,016,289  100.00  0              0.00   0

 THAT Paul Pagano be, and hereby is, re-elected as a director of the Company to
 hold office until the conclusion of the next Annual General Meeting of the
 Company.
 Resolution 6 (Common)                                                            13,016,289  100.00  0              0.00   0

 THAT David Anderson be, and hereby is, re-elected as a director of the Company
 to hold office until the conclusion of the next Annual General Meeting of the
 Company.
 Resolution 7 (Common)                                                            13,016,289  100.00  0              0.00   0

 THAT Andrew Boteler be, and hereby is, re-elected as a director of the Company
 to hold office until the conclusion of the next Annual General Meeting of the
 Company.
 Resolution 8 (Common)                                                            13,016,289  100.00  0              0.00   0

 THAT Sara Barrington be, and hereby is, re-elected as a director of the
 Company to hold office until the conclusion of the next Annual General Meeting
 of the Company.
 Resolution 9 (Common)                                                            13,016,289  100.00  0              0.00   0

 THAT James McCullough be, and hereby is, re-elected as a director of the
 Company to hold office until the conclusion of the next Annual General Meeting
 of the Company.
 Resolution 10 (Common)                                                           13,016,289  100.00  0              0.00   0

 THAT Crowe UK LLP be, and hereby is, reappointed as auditor of the Company to
 hold office until the conclusion of the next Annual General Meeting of the
 Company.

 

The Company notes that, whilst Resolution 2 was passed with the required
majority, there was a sizable vote against it representing 23.19% of
shareholders who voted. The Company acknowledges these votes and will engage
with shareholders to understand further the reasons behind this vote. The
Board will provide an update on this engagement and any actions taken will be
published within six months of the AGM.

 

As at 4 May 2023, there were 25,485,982 common shares in issue. Stockholders
are entitled to one vote per common share. Votes withheld are not votes in law
and so have not been included in the calculation of the proportion of votes
for and against a resolution.

 

 

For further information please contact:

 

 LungLife AI, Inc.                                         www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                          Via Walbrook PR
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Joint Broker)      Tel: +44 (0)20 7597 5970
 Virginia Bull / Cameron MacRitchie / Lydia Zychowska

 Goodbody (Joint Broker)                                   Tel: +44 (0) 20 3841 6202 / +353 (1) 667 0420

 Tom Nicholson / Stephen Kane

 Walbrook PR Limited                                        Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
                                                           (mailto:LungLifeAI@walbrookpr.com)
 Stephanie Cuthbert / Alice Woodings / Phillip Marriage    Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

About Lunglife AI

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com/) .  Our Purpose is to be a driving force in the
early detection to lung cancer.  Our Vision is to invert the 20:80 ratio such
that in years to come at least 80% of lung cancer is detected early.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGEAKSLELPDEFA